Psyence Biomedical Ltd. Common Shares (PBM) - Total Liabilities
Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) has total liabilities worth $943.07K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Psyence Biomedical Ltd. Common Shares (PBM) net asset momentum to track the company's year-over-year net asset growth rate.
Psyence Biomedical Ltd. Common Shares - Total Liabilities Trend (2021–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's total liabilities have evolved over time, based on quarterly financial data.
Psyence Biomedical Ltd. Common Shares Competitors by Total Liabilities
The table below lists competitors of Psyence Biomedical Ltd. Common Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Infinity Mining Ltd
AU:IMI
|
Australia | AU$392.72K |
|
Ecobuilt Holdings Bhd
KLSE:0059
|
Malaysia | RM150.94 Million |
|
Softimat S.A.
BR:SOFT
|
Belgium | €867.00K |
|
Yunji Inc
NASDAQ:YJ
|
USA | $273.75 Million |
|
Ecofin Global Utilities and Infrastructure Trust plc
LSE:EGL
|
UK | GBX16.93 Million |
|
Birddog Technology Ltd
AU:BDT
|
Australia | AU$2.15 Million |
|
Ordissimo
PA:ALORD
|
France | €2.38 Million |
|
Constellation Technologies Ltd
AU:CT1
|
Australia | AU$793.97K |
Liability Composition Analysis (2021–2025)
This chart breaks down Psyence Biomedical Ltd. Common Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PBM market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Psyence Biomedical Ltd. Common Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Psyence Biomedical Ltd. Common Shares (2021–2025)
The table below shows the annual total liabilities of Psyence Biomedical Ltd. Common Shares from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $594.37K | -95.09% |
| 2024-03-31 | $12.10 Million | -15.18% |
| 2023-03-31 | $14.27 Million | -12.87% |
| 2022-03-31 | $16.38 Million | +16104.79% |
| 2021-03-31 | $101.08K | -- |
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more